- Home
- VTYX vs DCGO Comparison
VTYX vs DCGO Comparison
Compare VTYX & DCGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- DCGO
- Stock Information
- Founded
- VTYX 2018
- DCGO 2015
- Country
- VTYX United States
- DCGO United States
- Employees
- VTYX N/A
- DCGO N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- DCGO Managed Health Care
- Sector
- VTYX Health Care
- DCGO Health Care
- Exchange
- VTYX Nasdaq
- DCGO Nasdaq
- Market Cap
- VTYX 154.9M
- DCGO 144.7M
- IPO Year
- VTYX 2021
- DCGO N/A
- Fundamental
- Price
- VTYX $2.58
- DCGO $1.40
- Analyst Decision
- VTYX Buy
- DCGO Strong Buy
- Analyst Count
- VTYX 4
- DCGO 4
- Target Price
- VTYX $11.33
- DCGO $3.74
- AVG Volume (30 Days)
- VTYX 1.1M
- DCGO 473.8K
- Earning Date
- VTYX 08-15-2025
- DCGO 08-07-2025
- Dividend Yield
- VTYX N/A
- DCGO N/A
- EPS Growth
- VTYX N/A
- DCGO N/A
- EPS
- VTYX N/A
- DCGO N/A
- Revenue
- VTYX N/A
- DCGO $520,500,658.00
- Revenue This Year
- VTYX N/A
- DCGO N/A
- Revenue Next Year
- VTYX N/A
- DCGO $4.08
- P/E Ratio
- VTYX N/A
- DCGO N/A
- Revenue Growth
- VTYX N/A
- DCGO N/A
- 52 Week Low
- VTYX $0.78
- DCGO $1.23
- 52 Week High
- VTYX $3.39
- DCGO $5.68
- Technical
- Relative Strength Index (RSI)
- VTYX 46.35
- DCGO 43.97
- Support Level
- VTYX $2.63
- DCGO $1.31
- Resistance Level
- VTYX $2.92
- DCGO $1.54
- Average True Range (ATR)
- VTYX 0.22
- DCGO 0.08
- MACD
- VTYX -0.08
- DCGO -0.00
- Stochastic Oscillator
- VTYX 0.00
- DCGO 36.54
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.